Advanced search×

Breast cancer treatment and cognitive function: the current state of evidence, underlying mechanisms and potential treatments.

Vodermaier A

Womens Health (Lond Engl) 5(5):503-16 (2009) PMID 19702450

DOI: 10.2217/whe.09.36
Version: za2963e q8za7 q8zba q8zcd q8zd5 q8ze9 q8zff q8zga
Buy PDF

Similar articles you may find interesting…

  1. GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors.
    Andrea Morandi, Lesley-Ann Martin, and Clare M Isacke

    Cancer Res (2013) PMID 23650283

    We report the findings of a multidisciplinary strategy to address the impact of GDNF-RET signaling in the response to AI treatment. In breast cancer cells in 2D and 3D culture, GDNF-mediated RET signaling is enhanced in a model of AI resistance. Further, GDNF-RET signaling promoted the survival of A...
    Buy PDF
  2. A randomized controlled trial of group cognitive behavioral therapy for Chinese breast cancer patients with major depression.
    Jianyin Qiu, Weijun Chen, and Min Yang

    J Psychosom Obstet Gynaecol (2013) PMID 23646866

    Patients in the GCBT group had a significant reduction in the 17-HAMD mean score by 9 points (p < 0.001) more reduction from baseline to six-month follow-up...
    Buy PDF
  3. Use of β-Blockers, Angiotensin-Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Risk of Breast Cancer Recurrence: A Danis...
    Gitte Vrelits Sørensen, Patricia A Ganz, and Thomas P Ahern

    J Clin Oncol (2013) PMID 23650417

    PURPOSETo estimate associations between use of β-blockers, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers (ARBs) and breast cancer recurrence in a large Danish cohort. PATIENTS AND METHODSWe enrolled 18,733 women diagnosed with nonmetastatic breast...
    Buy PDF